Human lung carcinomas express Fas ligand

Cancer Research

Volumn 57, Issue 6, 1997, Pages 1007-1012

  Niehans, Gloria A ^a   Brunner, Thomas ^b   Frizelle, Sandra P ^a   Liston, Jacob C ^a   Salerno, Christopher T ^a   Knapp, Dennis J ^a   Green, Douglas R ^b   Kratzke, Robert A ^a,c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^c VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; LUNG CARCINOMA; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD95; DNA, NEOPLASM; FAS LIGAND PROTEIN; HUMANS; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; RNA, MESSENGER; RNA, NEOPLASM; TUMOR CELLS, CULTURED;

EID: 0030933337     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Nagata, S., and Golstein, P. The Fas death factor. Science (Washington DC). 267: 1449-1456, 1995.
2. Trauth, B. C., Klas, C., Peters, A. M. J., Matzku, S., Möller, P., Falk, W., Debatin, K-M., and Krammer, P. H. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science (Washington DC), 245: 301-305, 1989.
3. Suda, T., Takahashi, T., Golstein, P., and Nagata, S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell, 75: 1169-1178, 1993.
4. Owen-Schaub, L. B., Yonehara, S., Crump, W. L., and Grimm, E. A. DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell. Immunol., 140: 197-205, 1992.
5. Klas, C., Debatin, K-M., Jonker, R. R., and Krammer, P. H. Activation interferes with the APO-1 pathway in mature human T cells. Int. Immunol., 625-630: 1993.
6. Yonehara, S., Ishii, A., and Yonehara, M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med., 769: 1747-1756, 1989.
7. Oehm, A., Behrman, I., Falk, W., Pawlita, M., Maier, G., Klas, C., Li-Weber, M., Richards, S., Dhein, J., Trauth, B. C., Ponsting, H., and Krammer, P. H. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor family: sequence identity with the Fas antigen. J. Biol. Chem., 267: 10709-10715, 1992.
8. Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S-I., Sameshima, M., Hase, A., Seto, Y., and Nagata, S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell, 66: 233-243, 1991.
9. Singer, G. G., and Abbas, A. K. The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity, 1: 365-371, 1994.
10. Alderson, M. R., Tough, T. W., Davis-Smith, T., Braddy, S., Falk, B., Schooley, K. A., Goodwin, R. G., Smith, C. A., Ramsdell, F., and Lynch, D. H. Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med., 181: 71-77, 1995.
11. Dhein, J., Walczak, H., Bäumler, C., Debatin, K-M., and Krammer, P. H. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature (Lond.), 373:438-441, 1995.
12. Brunner, T., Mogil, R. J., LaFace, D., Yoo, N. J., Mahboubi, A., Echeverri, F., Martin, S. J., Force, W. R., Lynch, D. H., Ware, C. F., and Green, D. R. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature (Lond.), 375: 441-444, 1995.
13. Ju, S-T., Panka, D. J., Cui, H., Ettinger, R., El-Khatib, M., Sherr, D. H., Stanger, B. Z., and Marshak-Rothstein, A. Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature (Lond.), 373: 444-448, 1995.
14. Watanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A., and Nagata, S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature (Lond.), 356: 314-317, 1992.
15. Takahashi, T., Tanaka, M., Brannan, C. I., Jenkins, N. A., Copeland, N. G., Suda, T., and Nagata, S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell, 76: 969-976, 1994.
16. Rieux-Laucat, F., Le Deist, F., Hivroz, C., Roberts, I. A. G., Debatin, K. M., Fischer, A., and de Billartay, J. P. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science (Washington DC), 265: 1347-1349, 1995.
17. Fisher, G. H., Rosenberg, F. J., Straus, S. E., Dale, J. K., Middleton, L. A., Lin, A. Y., Strober, W., Lenardo, M. J., and Puck, J. M. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell, 81: 935-946, 1995.
18. Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., and Ferguson, T. A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science (Washington DC), 270: 1189-1192, 1995.
19. Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A., and Duke, R. C. A role for CD95 ligand in preventing graft rejection. Nature (Lond.), 377: 630-632, 1995.
20. Lau, H. T., Yu, M., Fontana, A., and Stoeckert, C. J., Jr. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science (Washington DC), 273: 109-112, 1996.
21. Takahashi, T., Tanaka, M., Inazawa, J., Abe, T., Suda, T., and Nagata, S. Human Fas ligand, gene structure, chromosomal location and species specificity. Int. Immunol., 6: 1567-1574, 1994.
22. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J-C., and Tschopp, J. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science (Washington DC), 274: 1363-1366, 1996.
23. O'Connell, J., O'Sullivan, G. C., Collins, J. K., and Shanahan, F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med., 184: 1075-1082, 1996.
24. Strand, S., Hofmann, W. J., Hug, H., Muller, M., Otto, G., Strand, D., Mariani, S. M., Stremmel, W., Krammer, P. H., and Galle, P. R. Lymphocyte apoptosis induced by CD95 (APO-1 /Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat. Med., 2. 1361-1366, 1996.
25. Leithäuser, F., Dhein, J., Mechtersheimer, G., Koretz, K., Brüderlein, S., Henne, C., Schmidt, A., Debatin, K-M., Krammer, P. H., and Möller, P. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest., 69: 415-429, 1993.
26. 2+-independent T cell-mediated cytotoxicity. J. Exp. Med., 177: 195-200, 1993.
27. Lowin, B., Hahne, M., Mattmann, C., and Tschopp, J. Cytolytic T-cell cytotoxicity is mediated through perform and Fas lytic pathways. Nature (Lond.), 370: 650-652, 1994.
28. Kägi, D., Vignaux, F., Ledermann, B., Bürki, K., Depraetere, V., Nagata, S., Hengartner, H., and Golstein, P. Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity. Science (Washington DC), 265: 528-530, 1994.
29. Yang, Y., Mercep, M., Ware, C. F., and Ashwell, J. D. Fas and activation-induced Fas ligand mediate apoptosis of T cell hybridomas: inhibition of Fas ligand expression by retinoic acid and glucocorticoids. J. Exp. Med., 787; 1673-1682, 1995.
30. Cheng, J., Zhou, T., Liu, C., Shapiro, J. P., Brauer, M. J., Kiefer, M. C., Barr, P. J., and Mountz, J. D. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science (Washington DC), 263: 1759-1762, 1994.
31. Owen-Schaub, L. B., Radinsky, R., Kruzel, E., Berry, K., and Yonehara, S. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res., 54: 1580-1586, 1994.
32. Itoh, N., Tsujimoto, Y., and Nagata, S. Effect of bcl-2 on Fas antigen-mediated cell death. J. Immunol., 757: 621-627, 1993.
33. Jäättelä, M., Benedict, M., Tewari, M., Shayman, J. A., and Dixit, V. M. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene, 10: 2297-2305, 1995.
34. McGahon, A. J., Nishioka, W. K., Martin, S. J., Mahboubi, A., Cotter, T. G., and Green, D. R. Regulation of the Fas apoptotic cell death pathway by abl. J. Biol. Chem., 270: 22625-22631, 1995.
35. Weller, M., Malipiero, U., Aguzzi, A., Reed, J. C., and Fontana, A. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J. Clin. Invest., 95: 2633-2643, 1995.
36. Tanaka, M., Suda, T., Haze, K., Nakamura, N., Sato, K., Kimura, F., Motoyoshi, K., Mizuki, M., Tagawa, S., Ohga, S., Hatake, K., Drummond, A. H11 Nagata, S. Fas ligand in human serum. Nat. Med., 2: 317-322, 1996.
37. Krant, M. J., Manskopf, G., Brandrup, C. S., and Madoff, M. A. Immunologic alterations in bronchogenic cancer. Sequential study. Cancer (Phila.), 27: 623-631, 1968.
38. Brugarolas, A., and Takita, H. Immunologie status in lung cancer. Chest, 64: 427-430, 1973.
39. Ogasawara, J., Watanabe, F. R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., and Nagata, S. Lethal effect of the anti-Fas antibody in mice. Nature (Lond.), 364: 806-809, 1993.
40. Pardoll, D. M. Tumour antigens: a new look for the 1990s. Nature (Lond.), 369: 357-358, 1994.
41. Van den Eynde, B., and Brichard, V. G. New tumor antigens recognized by T cells. Curr. Opin. Immunol., 7: 674-681, 1995.
42. Cordon-Cardo, C., Fuks, Z., Drobnjak, M., Moreno, C., Eisenbach, L., and Feldman, M. Expression of HLA-A, B, C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res., 57: 6372-6380, 1991.
43. Restifo, N. P., Esquivel, F., Kawakami, Y., Yewdell, J. W., Mulé, J. J., Rosenberg, S. A., and Bennink, J. R. Identification of human cancers deficient in antigen processing. J. Exp. Med., 177: 265-272, 1993.
44. Chen, L., Ashe, S., Brady, W. A., Hellström, I., Hellström, K. E., Ledbetter, J. A., McGowan, P., and Linsley, P. S. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell, 71: 1093-1102, 1992.
45. Townsend, S., and Allison, J. P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (Washington DC), 259: 368-370, 1993.
46. Sulitzeanu, D. Immunosuppressive factors in human cancer. Adv. Cancer Res., 60: 247-271, 1993.
47. Mizoguchi, H., O'Shea, J. J., Longo, D. L., Loeffler, C. M., McVicar, D. W., and Ochoa, A. C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science (Washington DC), 255: 1795-1798, 1992.
48. Nakagomi, H., Petersson, M., Magnusson, I., Juhlin, C., Matsuda, M., Mellstedt, H., Taupin, J-L., Vivier, E., Anderson, P., and Kiessling, R. Decreased expression of the signal-transducing chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res., 53: 5610-5612, 1993.
49. Finke, J. H., Zea, A. H., Stanley, J., Longo, D. L., Mizoguchi, H., Tubbs, R. R., Wiltrout, R. H., O'Shea, J. J., Kudoh, S., Klein, E., Bukowski, R. M., and Ochoa, A. C. Loss of T-cell receptor ζ chain and p561ck in T-cells infiltrating human renal cell carcinomas. Cancer Res., 53: 5613-5616, 1993.
50. Leach, D. R., Krummel, M. F., and Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science (Washington DC), 277: 1734-1736, 1996.
51. Shimizu, E., Coxon, A., Otterson, G. A., Steinberg, S. M., Kratzke, R. A., Kim, Y. W., Fedorko, J., Oie, H., Johnson, B. E., Mulshine, J. L., Minna, J. D., Gazdar, A. F., and Kaye, F. J. RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene, 9: 2441-2448, 1994.
52. Carney, D. N., Gazdar, A. F., Bepler, G., Guccion, J. G., Marangos, P. J., Moody, T. W., Zweig, M. H., and Minna, J. D. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res., 45: 2913-2923, 1985.
53. Kratzke, R., Otterson, G. A., Lincoln, C. E., Ewing, S., Oie, H., Geradts, J., and Kaye, F. J. Immunohistochemical analysis of the p16INK4 cyclin dependent kinase inhibitor in malignant mesothelioma. J. Natl. Cancer Inst., 87: 1870-1875, 1995.
54. 706 residue of the retinoblastoma protein. J. Biol. Chem., 267: 25998-26003, 1992.
55. Sanger, F., Nicklen, S., and Coulson, A. R. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA, 74: 5463-5467, 1977.
56. Miller, R. T., and Estran, C. Heat-induced epitope retrieval with a pressure cooker: suggestions for optimal use. Appl. Immunohistochem., 3: 190-193, 1995.